Table 3.
Cell-derived blood-borne microvesicles from apparently healthy women and men separated by age, sex, and menopausal status
| Blood-borne microvesicles | 20–70 years old | 20–65 years old | 51–70 years old | |||
|---|---|---|---|---|---|---|
| Women ( N = 82) | Men ( N = 62) | Premenopausal women ( N = 58) | Men ( N = 59) | Postmenopausal women ( N = 24) | Men ( N = 33) | |
| Cellular origin of MV/μL plasma | ||||||
| Total erythrocyte-(CD235a) derived MV | 57 (23, 107) | 73 (44, 124) | 49* (19, 96) | 76 (45, 142) | 77† (50, 177) | 69 (40, 165) |
| Total leukocyte (CD45)-derived MV | 23 (16, 35) | 23 (17, 38) | 23 (16, 38) | 23 (17, 39) | 28 (16, 35) | 25 (18, 41) |
| Monocyte (CD14)-derived MV | 12 (7, 27) | 11 (6, 26) | 12 (7, 27) | 11 (6, 25) | 12 (6, 27) | 16 (8, 38) |
| T-cell (CD3)-derived MV | 6 (4, 9) | 5 (3, 9) | 6 (4, 9) | 5 (3, 10) | 6 (4, 13) | 5 (3, 7) |
| B-cell (CD19)-derived MV | 10 (5, 16) | 7 (4, 17) | 8 (4, 15) | 7 (4, 17) | 11 (6, 23) | 7 (4, 19) |
| Platelet (CD42a)-derived MV | 626* (293, 1156) | 486 (342, 868) | 687 (261, 1126) | 492 (349, 853) | 529 (362, 1298) | 508 (364, 921) |
| Endothelium (CD62E)-derived MV | 17* (9, 30) | 10 (4, 22) | 16* (7, 24) | 10 (5, 22) | 20* (11, 41) | 9 (5, 21) |
| Adipocyte (FABP4)-derived MV | 5 (3, 15) | 5 (2, 10) | 5 (3, 14) | 5 (1, 10) | 5 (2, 18) | 6 (3, 14) |
| Stem/progenitor cell (CD117)-derived MV | 4 (2, 8) | 6 (3, 10) | 3* (2, 7) | 6 (3, 10) | 5 (3, 8) | 7 (5, 10) |
| Senescent cell (p16-set)-derived MV | 7 (3, 13) | 5 (2, 12) | 7 (3, 14) | 5 (2, 12) | 6 (2, 12) | 6 (2, 18) |
Data are presented as median with 25th and 75th percentiles.
*Statistically significant (P < 0.05) differences in concentration of MV between women and age-matched men. †Statistically significant (P < 0.05) differences in concentration of MV between postmenopausal women and premenopausal women.